Goodwin Advises Royalty Pharma on Acquiring Royalty Interest in AstraZeneca’s cliramitug for Up To $425 Million From Neurimmune

The Life Sciences team advised Royalty Pharma plc (Nasdaq: RPRX) in acquiring a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug. Royalty Pharma will provide Neurimmune up to $425 million, including $125 million upfront, in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug. In the first quarter of 2027, Royalty Pharma will provide another $125 million in cash to Neurimmune, with the remaining $175 million payable based on the achievement of certain clinical and regulatory milestones.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and nonprofits through small and mid cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

The Goodwin transactions team was led by Jacqueline Mercier, Robert Crawford, Catherine Magazu, Alison Liou, and Bartek Sudol. The Goodwin IP team was led by Carl Morales, Maria Smith, and Pavel Puzerey. Reid Bagwell provided debt finance support, and Barry Bazian provided bankruptcy and restructuring support for the transaction.

For more information on the deal, please read the press release.